{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-023189","form_type":"8-K","ticker":"ELUT","cik":"0001708527","company_name":"ELUTIA INC.","filed_at":"2026-03-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.960654+00:00","generated_at":"2026-05-15T21:44:29.047680+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Elutia regains full compliance with Nasdaq minimum bid price and MVLS requirements","bullets":["Received Nasdaq notice on March 2, 2026, confirming compliance with minimum bid price rule (bid ≥ $1.00 for 10 consecutive days).","Received Nasdaq notice on February 5, 2026, confirming compliance with MVLS requirement (MVLS ≥ $35M for 11 consecutive days).","All Nasdaq continued listing requirements are now met; matters are closed; stock continues trading on Nasdaq Capital Market under symbol ELUT.","CFO Matt Ferguson cites investor confidence in drug-eluting biomatrix technology platform and market opportunity."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-023189","json":"https://secwatch.observer/filing/0001104659-26-023189.json","markdown":"https://secwatch.observer/filing/0001104659-26-023189.md","text":"https://secwatch.observer/filing/0001104659-26-023189.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708527/000110465926023189/0001104659-26-023189-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708527/000110465926023189/elut-20260304x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T21:44:29.047680+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}